SCHEDULE 13D: Accuray Secures $190 Million Senior Secured Financing Package and Issues Warrants to Lenders

Accuray Incorporated has finalized a new $190 million senior secured credit facility, including term loans and a revolving credit facility, and issued warrants to its lenders, primarily to refinance existing debt and bolster working capital.

Summary

• Accuray Incorporated entered into a Financing Agreement on June 6, 2025, securing new credit facilities totaling $190,000,000.
• The financing package includes a $30,000,000 Term Loan A, a $120,000,000 Term Loan B, a $20,000,000 Delayed Draw Term Loan facility, and a $20,000,000 revolving credit facility.
• The stated maturity date for these facilities is June 6, 2030.
• Proceeds from the Term Loans drawn on the Effective Date will be used to refinance the Existing Credit Agreement and other existing indebtedness, and to consummate the exchange of a portion of Existing Notes, with up to $70,000,000 initially deposited in an escrow account for this purpose.
• Revolving Loans drawn after the Effective Date are designated for working capital and general corporate purposes, while Delayed Draw Term Loans will be used for the exchange or redemption of any remaining Existing Notes.
• In connection with the financing, Accuray issued warrants to TCW Rescue Financing Fund II LP and West Virginia Direct Lending LLC.
• These warrants include 'Premium Warrants' entitling holders to purchase 8,733,528 shares of common stock at an exercise price of $1.68 per share, exercisable after six months and one day from the issue date.
• Additionally, 'Penny Warrants' were issued, allowing the purchase of 3,175,829 shares at an exercise price of $0.01 per share, exercisable from the issue date.
• The total shares issuable upon exercise of these initial warrants amount to 11,909,357 shares.
• The TCW Group, Inc., on behalf of its TCW Business Unit, reported beneficial ownership of 11,909,357 shares, representing approximately 10.3% of Accuray's common stock (calculated based on 103,726,251 shares outstanding as of May 31, 2025, plus the warrant shares).
• TCW Asset Management Company LLC, acting as collateral and administrative agent for the lenders, gained the right to appoint one director and two non-voting observers to Accuray's Board of Directors as part of a Governance Agreement.

Sentiment

Score: 4

Explanation: While securing significant financing is a positive for liquidity and debt refinancing, the high interest rates, substantial prepayment penalties, and very restrictive financial covenants indicate a challenging financial position and a high cost of capital. The granting of board representation to the lender also suggests a degree of control ceded by the company, collectively pointing to a financially constrained situation rather than robust health.

Positives

• Secured substantial financing of $190,000,000, providing critical capital for refinancing existing debt and supporting ongoing operations.
• The new credit facilities extend the company's debt maturity profile to June 6, 2030, offering longer-term financial stability.
• The inclusion of a $20,000,000 Delayed Draw Term Loan facility provides additional liquidity options for future needs, particularly for addressing remaining Existing Notes.
• The option to pay a portion of interest in kind (PIK) up to 6.00% per annum offers flexibility in managing cash flow, especially in periods of tight liquidity.
• The lenders, through TCW Asset Management Company LLC, will have board representation (one director) and observation rights (two non-voting observers), which could provide strategic guidance and enhanced oversight.

Negatives

• The financing comes with high interest rates: Reference Rate plus 7.50% per annum or Adjusted Term SOFR plus 8.50% per annum, indicating a high cost of capital and potentially a higher risk profile for the company.
• The PIK option, while offering cash flow flexibility, increases the principal amount of the loans, further escalating the total debt burden and future interest payments.
• Significant prepayment penalties ('Applicable Premium') ranging from 1.00% to 2.00% plus a 'Make-Whole Amount' apply if the loans are repaid early, making early debt reduction costly.
• The agreement imposes strict financial covenants, including Total Leverage Ratio and Fixed Charge Coverage Ratio thresholds that become progressively tighter over time, and minimum Liquidity requirements, which could limit operational flexibility.
• The loans are secured by first-priority liens on substantially all assets of the Issuer and its subsidiaries, significantly encumbering the company's asset base.
• The company is subject to mandatory prepayments based on Excess Cash Flow, Net Cash Proceeds from certain Dispositions and Sale and Leaseback Transactions, and non-Permitted Indebtedness or Extraordinary Receipts, which could reduce available cash for other corporate purposes.
• The Administrative Borrower is required to transition to a passive holding company structure by October 1, 2025, which may necessitate significant internal restructuring and could alter the company's operational focus.
• Limitations on cash holdings by Japanese subsidiaries (not to exceed $6,000,000) and a requirement to repatriate excess cash could impact international operational flexibility.
• The governance agreement grants the lender significant influence over the company's board, potentially impacting management autonomy and strategic decision-making.

Risks

• Failure to comply with strict financial covenants (Total Leverage Ratio, Fixed Charge Coverage Ratio, Liquidity) could trigger an Event of Default, leading to acceleration of the loans.
• Cross-default provisions mean that a default on other Indebtedness exceeding $5,000,000 could lead to the acceleration of the new credit facilities.
• Any event or development that could reasonably be expected to have a Material Adverse Effect on the company's operations, assets, liabilities, financial condition, or ability to perform obligations under the loan documents could constitute an Event of Default.
• Loss, suspension, or revocation of, or failure to renew, any material licenses or Permits, particularly those related to Healthcare Laws, could significantly disrupt business operations and trigger a default.
• Material violations of Healthcare Laws, including issues related to product manufacturing, marketing, or regulatory compliance, could lead to adverse consequences and an Event of Default.
• The occurrence of a Change of Control, as defined in the agreement, could trigger an Event of Default and lead to the acceleration of the loans.
• Interruption of manufacturing facility operations for more than 30 consecutive days (or 60 days even with business interruption insurance) could constitute an Event of Default.
• Unpaid judgments, orders, or awards exceeding $5,000,000 in aggregate (not covered by insurance) could lead to enforcement proceedings and an Event of Default.
• Any material adverse tax consequences resulting from granting and perfecting Liens in certain jurisdictions (e.g., Switzerland) could impact the company's financial health.
• Non-compliance with U.S. Treasury Department's Outbound Investment Rules could lead to legal and financial repercussions.
• Limitations on the funded indebtedness of the Chinese Joint Venture (not to exceed RMB 750,000,000) could restrict its growth or operational flexibility without lender consent.

Future Outlook

The financing agreement provides Accuray with capital to refinance existing debt and support general corporate purposes, including working capital. The availability of a Delayed Draw Term Loan facility offers future funding flexibility for addressing remaining Existing Notes. The company is also planning a significant internal restructuring to transition the Administrative Borrower into a passive holding company by October 1, 2025, which suggests a strategic shift in its operational structure.

Management Comments

• The company's management, through the execution of the Financing Agreement, indicates a commitment to refinancing existing obligations and securing capital for ongoing operations and strategic initiatives.
• The certification by an Authorized Officer regarding compliance with covenants and the accuracy of financial statements reflects management's responsibility for financial reporting and adherence to the agreement's terms.

Industry Context

This financing agreement is a significant event for Accuray, a company operating in the medical device industry. The high interest rates and restrictive covenants suggest that the company may be perceived as having a higher risk profile within its sector, possibly due to market conditions, specific company performance, or the nature of its existing debt. The need for substantial refinancing indicates a focus on strengthening the balance sheet and ensuring liquidity, which is a common theme for companies navigating competitive and capital-intensive healthcare technology markets. The detailed regulatory compliance requirements and intellectual property provisions underscore the importance of these aspects in the medical device industry.

Comparison to Industry Standards

• The interest rates (Reference Rate + 7.50% or SOFR + 8.50%) are notably high, suggesting that Accuray's cost of debt is above typical investment-grade benchmarks for established medical device companies. For example, larger, more stable players like Medtronic or Intuitive Surgical typically secure financing at much lower rates, reflecting their stronger credit profiles and market positions.
• The inclusion of a 'Make-Whole Amount' and significant prepayment premiums (up to 2.00% plus Make-Whole) is a strong indicator of a lender-friendly deal, common in distressed or high-yield financing, rather than standard corporate lending for healthy, growing companies in the medical technology sector.
• The tightening financial covenants (e.g., Total Leverage Ratio decreasing from 7.25:1.00 to 4.00:1.00 over time, Fixed Charge Coverage Ratio increasing from 0.70:1.00 to 1.60:1.00) are aggressive and require significant operational improvement to maintain compliance, which is more stringent than typical covenants for industry leaders who often have more flexible debt structures.
• The granting of board designation and observer rights to the lender (TCW Asset Management Company LLC) is a common feature in rescue or special situations financing, providing the lender with direct oversight and influence, which is less common in standard financing arrangements for publicly traded companies unless they are in a challenging financial position or undergoing significant restructuring.

Management Changes

Corporate Governance

Related Party Transactions

• The financing agreement itself constitutes a significant related party transaction, as TCW Asset Management Company LLC and its affiliates are now major lenders and warrant holders, and have gained board representation.
• The agreement includes a negative covenant restricting transactions with affiliates, requiring them to be conducted for fair consideration and on terms not materially less favorable than arms-length transactions, with certain exceptions and disclosure requirements for transactions exceeding $500,000.

Stakeholder Impact

• **Shareholders**: Face potential dilution from the exercise of warrants (initially 11,909,357 shares, plus potential future Delayed Draw Warrants). The high cost of debt and restrictive covenants could impact future profitability and shareholder returns. Lender representation on the board may influence strategic decisions.
• **Employees**: No direct impact on employees is explicitly stated, but the financial stability provided by the new financing could be positive. However, the mention of restructuring costs and business optimization expenses in the Consolidated EBITDA calculation might imply potential future workforce adjustments.
• **Customers/Suppliers**: No direct impact is mentioned. The emphasis on compliance with Healthcare Laws and Product Authorizations is generally positive for product quality and regulatory adherence, which benefits customers. The company's financial stability could also ensure continued supply and service.
• **Existing Creditors**: The financing is primarily used to refinance existing debt, including the Existing Credit Agreement and a portion of the Existing Notes, directly impacting the repayment and terms for these creditors.
• **New Lenders (TCW and affiliates)**: Benefit from first-priority liens on substantially all company assets, high interest rates, and significant prepayment premiums, providing strong security and potential returns. Board representation offers direct oversight and influence over the company's operations and financial strategy.

Next Steps

• File a shelf registration statement (Form S-3 or S-1) within 60 calendar days of the Issue Date to cover the resale of warrant shares.
• Ensure the shelf registration becomes effective within 45 calendar days (or 90 days if SEC reviews) of filing.
• Deliver customary insurance certificates and endorsements within 5 and 45 days, respectively, of the Effective Date.
• Deliver landlord waivers, collateral access agreements, and Control Agreements for Cash Management Accounts within 60 days of the Effective Date.
• Cause Accuray International Srl, the Hong Kong Guarantor, and Accuray Japan K.K. to deliver Foreign Security Documents within 90 days of the Effective Date.
• Enter into and maintain Foreign Currency Exposure Hedging Agreements within 30 days (or up to 45 days) of the Effective Date.
• Transition the Administrative Borrower to a passive holding company structure by October 1, 2025.
• Commence quarterly principal repayments for Term Loan A and Term Loan B on September 30, 2025.
• Make mandatory prepayments based on Excess Cash Flow, Net Cash Proceeds from certain Dispositions/Sale and Leaseback Transactions, and Extraordinary Receipts.
• Potentially draw Delayed Draw Term Loans after the delivery of financial statements for the fiscal quarter ending December 31, 2025, to redeem remaining Existing Notes.

Key Dates

Recommendation

Keywords

Accuray, Financing Agreement, Term Loan, Revolving Credit Facility, Warrants, Debt Refinancing, Corporate Governance, SEC Filing, Schedule 13D, TCW Asset Management, Healthcare Law, Medical Devices, Financial Covenants, Liquidity, Capital Raise, Prepayment Penalty, Anti-dilution, Shareholder Rights